China’s biotech ascent forces US industry to choose: Is the country an ally or an existential threat?

The U.S. biotech industry is grappling with a growing dilemma over its reliance on Chinese drug development, with investments totaling $60 billion in the first three months of 2026 alone—on pace to double last year’s spending. While the rapid pace of Chinese drug development offers cost-effective opportunities for American firms, it has sparked fierce internal debates about whether partnerships with Chinese companies undermine U.S. innovation or are a necessary part of global competition. Some executives warn that China could replicate its dominance in sectors like rare earths and electric vehicles, eventually leveraging its biotech advancements to threaten American industry. A CEO of a U.S. biotech firm compared Chinese firms to 'coke dealers of globalism,' suggesting they manipulate dependencies for strategic advantage. Others dismiss these concerns, arguing that resistance to Chinese collaboration is outdated and that market competition will determine winners and losers. A middle faction acknowledges the risks but insists that without government intervention, firms will continue investing in China to avoid falling behind competitors. One investor admitted that ethical concerns are often sidelined in favor of profit, with deals worth up to $100 million driving decision-making. Most industry figures, however, remain silent due to fears of retaliation—from Chinese partners, venture capitalists, or even a future U.S. administration. Jason Kelly, CEO of Ginkgo Bioworks, is a rare public voice in the debate, advocating against Chinese dependency through media appearances and direct outreach. His stance highlights the broader tension: whether the U.S. should embrace China as a partner in drug development or treat it as an existential threat to its trillion-dollar biotech sector. The divide reflects deeper anxieties about economic security and the future of American innovation in a globalized market.